At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRTX Cortexyme Inc.
Post-Market Trading 11-22 17:58:13 EST
1.95
+0.00
0.00%
High1.95Low1.95Vol0.00
Open1.95D1 Closing1.95Amplitude0.00%
Mkt Cap70.49MTradable Cap48.29MTotal Shares36.15M
T/O521.88KT/O Rate0.00%Tradable Shares24.77M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name
Business Wire  ·  2022-08-01
Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name
CRTX stock on watch as company plans name change (NASDAQ:CRTX)
Seeking Alpha  ·  2022-07-27
CRTX stock on watch as company plans name change (NASDAQ:CRTX)
Cortexyme to change name and ticker symbol next month
seekingalpha  ·  2022-07-27
Cortexyme to change name and ticker symbol next month
BRIEF-Cortexyme Corporate Name Change To Quince Therapeutics To Take Effect On August 1, 2022
Reuters  ·  2022-07-27
BRIEF-Cortexyme Corporate Name Change To Quince Therapeutics To Take Effect On August 1, 2022
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
Business Wire  ·  2022-07-27
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
Business Wire  ·  2022-06-21
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
Cortexyme Appoints June Bray to its Board of Directors
Business Wire  ·  2022-06-13
Cortexyme Appoints June Bray to its Board of Directors
Cortexyme Successfully Completes Acquisition of Novosteo
Business Wire  ·  2022-05-20
Cortexyme Successfully Completes Acquisition of Novosteo
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
Business Wire  ·  2022-05-12
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Benzinga  ·  2022-05-10
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Cortexyme agrees to acquire biotech company Novosteo
seekingalpha  ·  2022-05-10
Cortexyme agrees to acquire biotech company Novosteo
BRIEF-Cortexyme Announces Agreement To Acquire Novosteo
Reuters  ·  2022-05-10
BRIEF-Cortexyme Announces Agreement To Acquire Novosteo
Is Cortexyme (NASDAQ:CRTX) In A Good Position To Deliver On Growth Plans?
Simply Wall St.  ·  2022-05-06
Is Cortexyme (NASDAQ:CRTX) In A Good Position To Deliver On Growth Plans?
Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves
Benzinga  ·  2022-05-03
Cortexyme Announces Further Layoffs, Chief Medical Officer Leaves
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Benzinga  ·  2022-05-03
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
BRIEF-Cortexyme - Co Is Further Reducing Headcount By 36%, Bringing Total Reduction To 67% From January 2022 Headcount Levels
Reuters  ·  2022-05-03
BRIEF-Cortexyme - Co Is Further Reducing Headcount By 36%, Bringing Total Reduction To 67% From January 2022 Headcount Levels
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
Business Wire  ·  2022-03-21
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
Business Wire  ·  2022-03-15
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
Business Wire  ·  2022-03-14
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders
Business Wire  ·  2022-03-09
Cortexyme Announces Preclinical Data Highlighting Potential Therapeutic Benefits of Atuzaginstat for the Treatment of High-Risk Oral Potentially Malignant Disorders

Introduction

Company Name.
Cortexyme Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Issue price:
--